STRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sutro Biopharma Inc (STRO) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows strong technical indicators, positive analyst sentiment, and promising pipeline developments, despite recent financial challenges.
The technical indicators are bullish. The MACD histogram is positive at 0.755, RSI_6 is neutral at 79.459, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its R1 resistance level of 34.898, with potential to test R2 at 37.507.
Strong preclinical results for STRO-004 and other pipeline candidates presented at AACR.
Advancing clinical progress with potential best-in-class data by mid-
Multiple analyst upgrades with increased price targets, reflecting undervaluation.
Collaborations with Astellas and promising dual-payload ADC technology.
Weak financial performance in Q4 2025, with revenue down 21.35% YoY and net income dropping 35.45% YoY.
High implied volatility (IV_30d at 106.
and low IV percentile (3.19), indicating potential risk.
In Q4 2025, the company reported a revenue decline of 21.35% YoY to $11.65M, net income dropped 35.45% YoY to -$46.76M, and EPS fell 39.07% YoY to -$5.35. However, gross margin remained stable at 100%.
Analysts are overwhelmingly positive, with multiple upgrades and price target increases. Recent targets include $41 (Citizens), $38 (Leerink), and $55 (Deutsche Bank). Analysts highlight the undervaluation of the stock, strong clinical progress, and potential best-in-class data for STRO-004 by mid-2026.
